COVID vaccine offers limited protection, Pfizer CEO reveals

The Chief Executive Officer of Pfizer, Albert Bourla has said two shots of the COVID vaccine offer very limited protection if any against the Omicron variant.

Bourla, who disclosed this during an interview on CNBC’s “Squawk Box, also said Pfizer’s Omicron-specific vaccine will be ready by March.

This latest admission by Bourla is “critically important for the Supreme Court mandate cases,” said Dr. Meryl Nass, because both the employer and healthcare worker mandates require only the first two vaccinations.

“It is hard to see how any mandates could stand up,” said Nass, a practicing physician and member of the Children’s Health Defense scientific advisory committee.

READ ALSO: Proof that Fauci lied about COVID-19 exposed

Bourla’s revelation is a far cry from his earlier stand that the two-dose regimen was “100% effective.”

When a third, or booster dose, is administered the vaccine offers only “reasonable protection” against hospitalization and death from Omicron and “less protection against infection,” Bourla said.

Journalist Jordan Schachtel speculated Bourla admitted the ineffectiveness of Pfizer’s vaccine against Omicron to prop up the vaccine maker’s newest and upcoming product: an Omicron-specific vaccine.

It’s estimated that Pfizer made $33.5 billion in COVID vaccine revenue in 2021, and the company expects similar results this year.